• Employee safety and business continuity are top priorities
• Wide-ranging humanitarian and social engagement
• Group sales increase by 6.0 percent (Fx & portfolio adj.) to 12.845 billion euros
• EBITDA before special items up by 10.2 percent to 4.391 billion euros
• All divisions report higher sales and earnings – strong demand at Consumer Health
• Net income advances by 20.0 percent to 1.489 billion euros
• Core earnings per share increase by 9.9 percent to 2.67 euros
• Outlook for 2020: impact of COVID-19 not yet reliably quantifiable

• Stockholders able to exercise right to submit questions and cast votes in a timely manner
• Online stockholders’ meeting enables proposed dividend of 2.80 euros per share for 2019 to be paid on time and in full
• Baumann: “Reliability for our stockholders is very important, especially during the crisis”

Chairman of the Board of Management, Baumann: “Our emergency aid is designed to help support hospitals and hospital staff during the crisis.”

• Group sales advance by 3.5 percent (Fx & portfolio adj.) to 43.545 billion euros
• EBITDA before special items increases by 28.3 percent to 11.503 billion euros
• Core earnings per share up by 14.3 percent to 6.40 euros
• Net income rises 141.4 percent to 4.091 billion euros – gain of 1.637 billion euros on sale of Currenta stake
• Free cash flow of 4.214 billion euros above expectations
• Proposed dividend of 2.80 euros per share
• Crop Science shows solid performance in challenging environment, substantial increase in earnings due to acquired business
• Pharmaceuticals shows encouraging business development
• Sales growth at Consumer Health, earnings at prior-year level despite divestments
• Ongoing portfolio, structural and efficiency measures implemented successfully
• Glyphosate’s positive safety profile confirmed – appeal and mediation proceedings moving forward
• Outlook for 2020: increase in sales, earnings and free cash flow
• Ambitious sustainability targets set

• Werner Wenning to retire after over 50 years with Bayer
• Horst Baier proposed for election as new shareholder representative

• New herbicide molecule in early development announced; first new post-emergence mode of action for broad acre weed control in 30 years
• Bayer unveils a third pathway to breakthrough short stature corn through gene editing; two prior concepts advance to Phase 3
• Three generations of herbicide-tolerance traits in soybeans advance phases, representing the industry’s most robust pipeline of weed control biotechnology for soy
• Largest agricultural industry R&D investment of more than 2.3 billion euros annually

• “Decision of EPA corresponds to the long-standing assessments of leading international health authorities”, says Liam Condon, Bayer Board Member
• The Amicus brief of the U.S. Department of Justice in the Hardeman case also support Glyphosate´s safety